FDA ALERT
FDA ALERT
01/29/2024
Anthony Calabro, MA
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
01/29/2024
FDA ALERT
FDA ALERT
11/30/2023
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
FDA Alert
FDA Alert
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
FDA Alert
09/28/2023
Anthony Calabro, MA
The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.
09/28/2023
FDA Alert
FDA Alert
09/15/2023
Anthony Calabro, MA
The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.
09/15/2023
FDA alert
FDA alert
08/25/2023
Jessica Ganga
Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.
08/25/2023
FDA Alert
FDA Alert
08/24/2023
Anthony Calabro, MA
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
08/24/2023
FDA alert
FDA alert
05/04/2023
Jessica Ganga
After an ongoing study, the FDA approves the first vaccine for the highly contagious respiratory virus for us in the United States.
05/04/2023
FDA Alerts
FDA Alerts
04/03/2023
Jessica Ganga
The FDA approves the overdose medication for over-the-counter use after data supports its safe use.
04/03/2023
FDA ALERT
FDA ALERT
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015